Beigene 311-308 / MAHOGANY

About this trial

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Patient Profile

Key Inclusion Criteria: Histologically confirmed grade 1-3a FL or MZL Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy Need for systemic therapy for FL or MZL Measurable disease by computed tomography or magnetic resonance imaging Adequate bone marrow, liver and renal function Key Exclusion Criteria: Transformation to aggressive lymphoma Requiring ongoing need for corticosteroid treatment Clinically significant cardiovascular disease Prior malignancy within the past 2 years Active fungal, bacterial, and/or viral infection that requires systemic therapy

Where’s this trial being run?

St James’s Hospital and University Hospital Waterford

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	Beigene 311-308 / MAHOGANY
Number:	24-30
Full Title:	A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Principal Investigator:
Type:	Industry Sponsored
Sponsor:	BeiGene
Recruitment Started:	Global: 10-Mar-2022 Ireland:

Global Recruitment Target:
Ireland Recruitment Target: